IMGN : Summary for ImmunoGen, Inc. - Yahoo Finance

U.S. Markets closed

ImmunoGen, Inc. (IMGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.84-0.05 (-2.65%)
At close: 4:00 PM EST
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close1.89
Bid1.80 x 1000
Ask1.88 x 500
Day's Range1.83 - 1.95
52 Week Range1.51 - 14.10
Avg. Volume1,327,796
Market Cap160.63M
PE Ratio (TTM)-1.03
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Enzo Biochem, Inc. (ENZ): Are Hedge Funds Right About This Stock?
    Insider Monkey2 days ago

    Enzo Biochem, Inc. (ENZ): Are Hedge Funds Right About This Stock?

    Hedge funds run by legendary names like Nelson Peltz and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]

  • Hedge Funds Are Selling ImmunoGen, Inc. (IMGN)
    Insider Monkey4 days ago

    Hedge Funds Are Selling ImmunoGen, Inc. (IMGN)

    It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. The Standard and Poor’s 500 Index returned 7.6% over […]

  • Business Wire6 days ago

    Preclinical Data on IMGN632, a Novel CD123-Targeting ADC, Presented at ASH Annual Meeting

    ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that preclinical data on IMGN632, a novel CD123-targeting ADC, were presented today at the 58th American Society of Hematology Annual Meeting in San Diego, CA.